Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "Cardiovascular"

371 News Found

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
News | April 07, 2024

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India

Vericiguat works on a pathway not currently targeted by existing heart failure treatments


Abbott receives FDA approval for TriClip
Drug Approval | April 04, 2024

Abbott receives FDA approval for TriClip

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery


Bayer strengthens pharma portfolio with new cardiology drug acoramidis
News | March 06, 2024

Bayer strengthens pharma portfolio with new cardiology drug acoramidis

Acquisition of exclusive commercialization rights for European markets


AstraZeneca completes acquisition of Icosavax
News | February 21, 2024

AstraZeneca completes acquisition of Icosavax

The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus


Medanta launches monthly talk show around cardiac care - 'Heart 2 Heart'
Healthcare | February 15, 2024

Medanta launches monthly talk show around cardiac care - 'Heart 2 Heart'

The talk show will be held monthly via Medanta's YouTube, Facebook and LinkedIn channe


Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India
News | January 17, 2024

Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India

Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa


Lupin launches Varenicline Tablets in US
News | January 11, 2024

Lupin launches Varenicline Tablets in US

Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US


Shanghai Argo announces multi-program RNAi licenses with Novartis
News | January 11, 2024

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.